Skip to main content

Table 3 Quality assessment of registration information on special items (n, %)

From: Calling for improved quality in the registration of traditional Chinese medicine during the public health emergency: a survey of trial registries for COVID-19, H1N1, and SARS

No. Item name COVID19 (n = 129) H1N1 (n = 7) Total (n = 136)
13. Interventions
 13.1 Intervention name 129 (100.0%) 7 (100.0%) 136 (100.0%)
 13.2 Ingredients or detail technique 13 (10.1%) 1 (14.3%) 14 (10.3%)
 13.3 Form 55 (42.6%) 4 (57.1%) 59 (43.4%)
 13.4 Dosage and frequency 20 (15.5%) 4 (57.1%) 24 (17.6%)
 13.5 Treatment duration 6 (4.7%) 0 (0.0%) 6 (4.4%)
 13.6 Control group 103 (79.8%) 7 (100.0%) 110 (80.9%)
 Total average 54.3 (42.1%) 3.8 (54.8%) 58.1 (42.7%)
14. Key inclusion and exclusion criteria
 14.1 Criteria of inclusion and exclusion 129 (100.0%) 7 (100.0%) 136 (100.0%)
 14.2 Gender 129 (100.0%) 7 (100.0%) 136 (100.0%)
 14.3 Age 109 (84.5%) 7 (100.0%) 116 (85.3%)
 14.4 Diagnosis criteria—Western medicine 45 (34.9%) 2 (28.6%) 47 (34.6%)
 14.5 With healthy human volunteer 1 (0.8%) 0 (0.0%) 1 (0.7%)
 Total average 82.6 (64.0%) 4.6 (65.7%) 87.2 (64.1%)
15. Study type
 15.1 Type of study 129 (100.0%) 7 (100.0%) 136 (100.0%)
 15.2 Method of allocation (randomized/non-randomized) 107 (82.9%) 5 (71.4%) 112 (82.4%)
 15.3 Masking (is masking used and, if so, who is masked) 46 (35.7%) 2 (28.6%) 48 (35.3%)
 15.4 Assignment (single arm, parallel, crossover, or factorial) 107 (82.9%) 7 (100.0%) 114 (83.8%)
 15.5 Allocation concealment mechanism 6 (4.7%) 0 (0.0%) 6 (4.4%)
 15.6 Phase (if applicable) 79 (61.2%) 5 (71.4%) 84 (61.8%)
 Total average 79.0 (61.2%) 4.3 (61.9%) 83.3 (61.3%)
19. Primary outcome(s)
 19.1 Name 128 (99.2%) 7 (100.0%) 135 (99.3%)
 19.2 Measurement of primary outcome(s) 2 (1.6%) 0 (0.0%) 2 (1.5%)
 19.3 Time point of measurements 17 (13.2%) 1 (14.3%) 18 (13.2%)
 Total average 49.0 (38.0%) 2.7 (38.1%) 51.7 (38.0%)
20. Key secondary outcome(s)
 20.1 Name 89 (69.0%) 7 (85.7%) 96 (70.6%)
 20.2 Measurements of key secondary outcomes 2 (1.6%) 0 (0.0%) 2 (1.5%)
 20.3 Time point of measurements 15 (11.6%) 1 (14.3%) 16 (11.8%)
 Total average 35.3 (27.4%) 2.7 (38.1%) 38.0 (27.9%)
21. Ethics review
 21.1 Ethics review status 125 (96.9%) 6 (83.3%) 131 (96.3%)
 21.2 Date of approval 98 (76.0%) 4 (69.0%) 102 (75.0%)
 21.3 Name of ethics committee(s) 105 (81.4%) 4 (78.6%) 109 (80.1%)
 21.4 Contact details of ethics committee(s) 104 (80.6%) 0 (40.5%) 104 (76.4%)
 Total average 108.0 (83.7%) 4.0 (57.1%) 112.0 (82.4%)
23. Summary results
 23.1 Date of posting of result summaries 0 (0%) 0 (0%) 0 (0%)
 23.2 Date of the first journal publication of results 0 (0%) 0 (0%) 0 (0%)
 23.3 URL hyperlink(s) related to results or a full reference list of publications 0 (0%) 0 (0%) 0 (0%)
 23.4 Baseline characteristics 0 (0%) 0 (0%) 0 (0%)
 23.5 Participant flow, adverse events 0 (0%) 0 (0%) 0 (0%)
 23.6 Adverse events 0 (0%) 0 (0%) 0 (0%)
 23.7 Outcome measures 0 (0%) 0 (0%) 0 (0%)
 23.8 URL link to protocol file(s) with version and date 0 (0%) 0 (0%) 0 (0%)
 Changes to protocol 0 (0%) 0 (0%) 0 (0%)
 Total average 0 (0%) 0 (0%) 0 (0%)
Total special items average report percentage (%) 45.6% 45.1% 45.6%
  1. COVID-19 severe acute respiratory syndrome coronavirus 2, H1N1 H1N1 influenza